PuraMed BioScience, Inc. Outlines 2012 Marketing Plans for Clinically Tested Migraine Treatment LipiGesic(R)

by **Tee** Fri Dec 30, 2011 5:34 am

SCHOFIELD, Wis., Dec. 21, 2011 /PRNewswire via COMTEX/ -- PuraMed BioScience, Inc. PMBS 0.00% announced today, an outline of its plans for the national product launch of its clinically tested migraine treatment LipiGesic(R) M.

The Company has always emphasized science as the key to their success and this year three of the top headache researchers in the United States conducted a Double-blind, Placebo controlled, clinical trial of LipiGesic(R) M. The study was peer reviewed and published in the top-tier medical journal Headache Volume 51, Number 7, July/August 2011. The study demonstrated that the product was safe, highly effective and is recommended as a First Line treatment (the primary or first treatment to try) for migraine headaches, to the medical community.

http://www.marketwatch.com/story/puramed-bioscience-inc-outlines-2012-marketing-plans-for-clinically-tested-migraine-treatment-lipigesicr-m-2011-12-21